The Order of Draw Series: Part Six - Potassium Oxalate & Sodium Fluoride Tubes

For newer phlebotomists, the gray tube might seem straightforward—it’s for glucose testing, it goes last, and you probably don’t draw it as often as the other tubes. But this unassuming tube has a fascinating dual purpose that extends beyond routine fasting glucose tests, with applications in both clinical and forensic settings where the absolute accuracy of glucose or alcohol measurements matters most.

Understanding why the gray tube exists, how it works, and why it occupies the final position in our collection sequence isn’t just about memorizing another protocol. It’s about recognizing that every tube in our phlebotomy tray represents decades of scientific development aimed at protecting one thing: the truth about what’s actually happening in a patient’s blood.

The Dual-Additive System: Two Preservatives, One Mission

Unlike most other collection tubes that contain a single additive, the gray tube typically contains two distinct substances working together:

Sodium fluoride (NaF) - the primary preservative and glycolysis inhibitor Potassium oxalate - the anticoagulant

The standard concentration is approximately 2-4 mg of sodium fluoride per milliliter of blood, with potassium oxalate at roughly 2 mg per milliliter. This specific ratio was carefully calibrated through decades of research to provide optimal preservation without interfering with glucose testing methods.

Some manufacturers make gray tubes with EDTA instead of potassium oxalate as the anticoagulant, but these are quite rare—particularly in US clinical and forensic settings. The vast majority of gray tubes you’ll encounter contain potassium oxalate. Sodium fluoride remains the constant across all versions—it’s the star of this particular show. The tube cap color (gray) has become internationally recognized as the indicator for “glucose preservation tube,” regardless of which anticoagulant accompanies the sodium fluoride.

What the Gray Tube Tests For

The gray tube has three primary uses in laboratory medicine:

Glucose testing - This is the primary and most common use. Gray tubes are drawn for fasting glucose tests, oral glucose tolerance tests (OGTT), random glucose monitoring, and any situation requiring accurate plasma glucose measurement.

Lactate testing - Some laboratories use gray tubes for lactate measurements, as lactate is also produced through glycolysis and benefits from the same preservative properties that protect glucose.

Blood alcohol testing - Gray tubes are used for blood alcohol concentration (BAC) testing when legally defensible results are required, or if testing will be delayed.

For experienced phlebotomists working in hospital settings, you’ve probably noticed that glucose testing for comprehensive metabolic panels (CMP) or basic metabolic panels (BMP) typically doesn’t use a gray tube—those glucose values come from heparin or serum tubes. The gray tube is reserved for situations requiring the most accurate glucose measurement possible, or where testing may be delayed for a few hours or a few days.

Potassium Oxalate: The Anticoagulant Partner

Potassium oxalate anticoagulates blood through calcium chelation—it binds to calcium ions, making them unavailable for the coagulation cascade. This is similar to EDTA and sodium citrate, but with important differences.

EDTA keeps calcium in solution but bound; oxalate forms calcium oxalate crystals that precipitate out. You can sometimes see these tiny crystals in gray tubes. This is why gray tubes can’t be used for calcium testing—the calcium precipitates out entirely.

Sodium citrate’s calcium chelation is reversible (which is why it works for coagulation testing—the lab can add calcium back). Oxalate’s chelation is essentially irreversible.

Heparin works completely differently—it enhances antithrombin activity rather than removing calcium.

For newer phlebotomists: oxalate prevents clotting by removing calcium, so you absolutely cannot use a gray tube for calcium testing.

Sodium Fluoride: The Glycolysis Inhibitor

Now for the main attraction. Sodium fluoride’s primary job is to prevent glycolysis—the metabolic process by which cells break down glucose for energy.

Here’s why this matters: After blood is drawn, the cells in that blood (especially red blood cells, white blood cells, and platelets) are still metabolically active. They’re still consuming glucose. Without something to stop this process, the glucose concentration in your blood sample will drop over time as cells continue to metabolize it.

Studies from the 1950s and 1960s demonstrated that glucose in whole blood without any preservative drops at a rate of approximately 5-7% per hour at room temperature. In a patient with a starting glucose of 100 mg/dL, that means after two hours, their sample might read 86-90 mg/dL. The lower reading is an artifact of delayed testing. You can see how this could become extra problematic after some time.

Think of it like this: Glycolysis is an assembly line with ten stations, each performing a specific step to break down glucose. Sodium fluoride walks up to station nine and shuts it down completely. Once that one critical station stops, the entire assembly line backs up and halts. No more glucose gets consumed.

Specifically, sodium fluoride inhibits an enzyme called enolase that works at step nine of the glycolysis pathway. Block enolase, and you essentially halt glycolysis before it can significantly deplete glucose in the sample.

Interestingly, sodium fluoride’s inhibition isn’t immediate. It can take 2-4 hours for sodium fluoride to fully inhibit glycolysis, however it’s only at 1-2% per hour, instead of 5-7%. This is why clinical laboratories that need glucose results quickly often accept gold or red serum tubes instead of gray tubes—if the sample is processed within an hour, the glucose drop is minimal and clinically acceptable for most purposes.

But when accuracy matters most—when you’re diagnosing diabetes, monitoring glycemic control, or making decisions about insulin dosing—the gray tube provides the gold standard for glucose stability. Glucose in a properly collected gray tube remains stable for up to 24 hours at room temperature and several days when refrigerated.

Sodium Fluoride’s Second Superpower: Antimicrobial Properties

Sodium fluoride is also an antimicrobial agent that prevents bacterial growth in blood samples. This matters because bacteria and yeast can both produce and consume alcohol. If a blood sample becomes contaminated with microorganisms, bacteria can ferment glucose and produce ethanol (creating false positives), or metabolize existing ethanol (causing false negatives).

Sodium fluoride prevents this by inhibiting microbial growth throughout storage. This is why gray tubes are used for blood alcohol testing—the sodium fluoride ensures that the measured alcohol reflects what was actually in the blood at collection, not what bacteria produced or consumed during storage.

I drew blood for a forensic testing company, and we used only gray tubes for drug and alcohol testing. These specimens sometimes sat for weeks before analysis, and the sodium fluoride ensured specimen integrity throughout that time.

The History: From Sweet Urine to Standardized Testing

The story of glucose testing is intimately connected to the history of diabetes mellitus—literally “sweet urine sickness.”

Ancient physicians in India, China, and Greece noted that some patients’ urine attracted ants and flies due to its sweetness. In 1674, English physician Thomas Willis described the urine of diabetic patients as “wonderfully sweet as if it were imbued with honey or sugar” (gross). But it wasn’t until 1776 that English physiologist Matthew Dobson proved that the sweetness was indeed due to sugar, and that the sugar was also present in the blood.

The development of practical blood glucose measurement began in 1913, but the breakthrough came in 1921 with the Folin-Wu blood glucose method, which made glucose testing accessible to clinical laboratories.

Researchers noticed that glucose concentration drops in blood after collection, with discrepancies between immediately tested samples and those tested after delays. The use of sodium fluoride as a glycolysis inhibitor was first proposed in the 1940s, revolutionizing glucose testing by allowing specimens to be collected and tested in batches without falsely low results.

The standardization of gray-top tubes came in the 1970s as part of the broader movement to standardize blood collection tubes by color. By the 1980s and 1990s, as plasma glucose became the standard specimen type for glucose testing (replacing serum glucose), the gray tube with its combination of anticoagulant and preservative became the definitive collection method for accurate glucose measurement.

Why Last in the Order of Draw?

The gray tube occupies the final position in the CLSI order of draw because both sodium fluoride and potassium oxalate are among the most interfering additives in our entire phlebotomy tray.

Potassium oxalate chelates calcium (preventing clotting), draws water from cells (shrinking them and decreasing hematocrit by up to 10%), causes severe platelet aggregation, affects cell morphology, and directly inhibits multiple enzymes including amylase, LDH, and alkaline phosphatase.

Sodium fluoride alters cell morphology, promotes hemolysis by depleting cellular ATP, interferes with electrolyte measurements, and inhibits enzymatic immunoassays used in many modern laboratory tests.

If either additive contaminates earlier tubes, specimens can be completely invalidated—serum tubes that won’t clot, lavender tubes with platelet clumping so severe that CBCs cannot be performed, chemistry tests with unmeasurable enzyme results, or false critical values that lead to inappropriate treatment.

The gray tube goes last to protect every other specimen from contamination by these two highly interfering substances.

What Happens If Gray Tube Additives Contaminate Other Tubes?

Let’s walk through what could happen if order of draw principles are violated and gray tube additives transfer to other collection tubes. These aren’t minor inconveniences—these are specimen failures and potentially dangerous result errors.

Gray tube drawn before lavender EDTA tubes:

Potassium oxalate transfers to the lavender tube intended for a complete blood count. The oxalate causes immediate platelet aggregation—platelets clump together in large masses. When the laboratory processes the specimen, they see platelet clumps throughout the sample.

Result: “Specimen rejected - platelet clumping present, unable to obtain accurate platelet count. Redraw required.”

The patient must be stuck again. If this is a difficult stick—elderly patient, poor veins, oncology patient with limited access—you’ve just caused unnecessary pain and anxiety because the tube order wasn’t followed.

Additionally, the potassium oxalate draws water from red blood cells into the plasma, shrinking the cells. The automated hematology analyzer measures a hematocrit of 38% when the patient’s actual hematocrit is 42%. The MCV (mean cell volume) is falsely low. The physician sees borderline anemia with microcytosis and orders iron studies, B12, and folate levels to investigate. Additional blood draws, additional testing, additional cost—all to investigate an artifact caused by contamination.

Gray tube drawn before serum tubes (red or gold):

Both sodium fluoride and potassium oxalate transfer to the gold SST tube intended for a comprehensive metabolic panel. The potassium oxalate chelates calcium and prevents normal clotting. After the standard 30-minute clotting time, the blood hasn’t formed a solid clot—instead, there are loose fibrin strands floating in partially clotted blood.

When centrifuged, the gel barrier can’t migrate properly through the incompletely clotted sample. Instead of clean separated serum on top, there’s a mixture of serum and fibrin. The automated chemistry analyzer detects fibrin interference and flags multiple tests as unreliable.

Result: “Specimen unsuitable for testing - inadequate clotting. Redraw required.”

Even if the specimen somehow makes it through processing, the sodium fluoride has inhibited enzymes in the sample. The amylase result is 15 U/L when the patient’s actual level is 95 U/L. The alkaline phosphatase is unmeasurable. The physician is looking at a chemistry panel with multiple impossible results and has to decide whether to trust any of the values or order a complete redraw.

Gray tube drawn before green heparin tubes:

Potassium oxalate and sodium fluoride contaminate a green tube intended for chemistry testing. The sodium fluoride alters cell membrane permeability, causing red blood cells to become fragile. During centrifugation, cells rupture. The plasma has a pink tinge—hemolysis.

The laboratory processes the specimen anyway since the hemolysis is mild. But the potassium from lysed red blood cells has leaked into the plasma. The potassium result is 6.2 mEq/L—critically high. The patient’s actual potassium is 4.1 mEq/L—completely normal.

The result gets called to the physician as a critical value. The physician orders a stat ECG, holds the patient’s ACE inhibitor, and considers whether to give kayexalate or transfer the patient to telemetry monitoring. All for hyperkalemia that doesn’t exist—it was created by gray tube contamination causing hemolysis.

Additionally, the sodium fluoride has inhibited lactate dehydrogenase (LDH). If the physician ordered LDH as part of a workup for hemolysis, liver disease, or malignancy, the result will be falsely low, potentially missing a diagnosis.

Gray tube drawn before light blue coagulation tubes:

Potassium oxalate transfers to the light blue sodium citrate tube. Now the specimen has two calcium-chelating anticoagulants instead of one. The calcium is even more thoroughly depleted than intended.

When the laboratory performs PT/INR testing, they add calcium chloride back to reverse the anticoagulation and measure clotting time. But the potassium oxalate has precipitated calcium out of solution as crystals—it’s not just bound like citrate, it’s gone. The added calcium isn’t sufficient to overcome both anticoagulants.

The PT is prolonged to 45 seconds (normal 11-13 seconds). The INR calculates to 4.8. The patient is on warfarin for atrial fibrillation with a target INR of 2.0-3.0. This result suggests dangerous over anticoagulation.

The physician holds the next two warfarin doses and orders vitamin K administration. But the patient’s actual INR is 2.4—perfectly therapeutic. By holding warfarin unnecessarily, the patient’s INR will drop below therapeutic range, increasing their stroke risk. The INR that looked dangerously high was an artifact of oxalate contamination.

Why these scenarios matter:

Notice that in none of these scenarios did the phlebotomist know they caused a problem. The blood drew normally. The tubes looked fine. The specimens went to the laboratory labeled correctly. But the order of draw violation created:

• Rejected specimens requiring redraw (patient discomfort, delayed results)
• False test results that appeared plausible (leading to unnecessary testing or inappropriate treatment)
• Enzyme results that were unmeasurable (requiring redraw or missing diagnoses)
• Cell morphology changes that invalidated hematology results
• Hemolysis that created false critical values

The gray tube goes last because its additives don’t just slightly alter results—they can completely invalidate specimens or create dangerous false results that look real. Every tube position in the order of draw exists to prevent exactly these scenarios.

Proper Collection Technique: Getting It Right

Gray tube collection follows the same basic principles as other anticoagulant tubes, with emphasis on the blood-to-additive ratio:

Fill to the line: Underfilling means too much preservative relative to blood volume, which can cause hemolysis. Overfilling means insufficient preservative—glycolysis inhibition may be incomplete and anticoagulation inadequate.

Invert properly: Immediately invert the gray tube 8-10 times to mix blood with additives. Don’t shake vigorously.

Document fasting status: Always confirm and document fasting time for fasting glucose tests.

When to use gray versus other tubes: Dedicated glucose testing (fasting glucose, OGTT, diabetes screening) should use gray tubes. Chemistry panels that include glucose as one of many tests typically use gold or red tubes since the slight glucose decline doesn’t significantly affect interpretation for those purposes.

Looking Forward: The Future of Glucose Testing

As continuous glucose monitors and point-of-care testing advance, the gray tube remains relevant. CGMs measure interstitial fluid glucose, not blood glucose, and still require laboratory confirmation for diagnosis. Point-of-care meters have accuracy limitations at extreme glucose values. When precision matters most, laboratory testing with proper specimen preservation remains the gold standard.

The gray tube represents over 80 years of refinement in glucose preservation technology. While the tubes may evolve, the fundamental principle—preventing post-collection metabolism from altering the results we report—remains as important as ever.

The Gray Tube in Context: Final Position, Critical Role

The gray tube sits at the end of our order of draw, but that final position doesn’t diminish its importance. In some ways, it exemplifies the entire purpose of phlebotomy: to collect a specimen that accurately reflects the patient’s physiological state at the moment of collection.

Blood glucose is one of the most commonly ordered tests in medicine. It guides diabetes diagnosis, monitors treatment effectiveness, informs insulin dosing, and helps evaluate countless other conditions where glucose metabolism matters. When we collect that blood in a gray tube with sodium fluoride and potassium oxalate, we’re ensuring that the number the laboratory reports—whether it’s 65 mg/dL or 350 mg/dL—represents the truth about that patient’s glucose concentration.

For newer phlebotomists learning the order of draw, the gray tube teaches an important lesson: every position in the sequence exists for a reason. Blood cultures come first to protect sterility. Coagulation tubes come early to avoid anticoagulant contamination. Serum tubes precede anticoagulant tubes to prevent clotting interference. EDTA tubes come late to protect calcium and potassium measurements. And gray tubes come last to ensure their preservatives don’t affect anything else we’re collecting.

For experienced phlebotomists, the gray tube represents the culmination of the order of draw—the final tube in a sequence that, when followed correctly, ensures every specimen we collect is as accurate and reliable as our technique can make it.

The gray tube may be last, but it’s definitely not least. It’s the guardian of glucose accuracy, a reminder that in phlebotomy, the details matter. Every tube, every position, every technique serves the same ultimate purpose: giving clinicians the accurate information they need to make decisions that affect people’s health and lives.

This post completes our Order of Draw Deep Dive series. From blood cultures to gray tubes, each position in the CLSI sequence represents decades of research, countless protocol refinements, and a commitment to specimen accuracy that defines professional phlebotomy practice. Understanding not just what the order is, but why it exists, transforms us from tube-fillers into guardians of diagnostic integrity.

What questions do you still have about the order of draw? Would you like to see more posts about special tubes like ACD tubes or royal blue tubes? Let us know!

Related Articles

These articles might be interesting for you as well: